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Abstract 
In this study we have used computational models to 
investigate the effects of nifedipine on two different cell 
types; the rat ventricular cell and the rat myometrial cell. 
Nifedipine is a calcium-channel blocker commonly used 
by health services around the world to treat both 
cardiovascular conditions (such as high blood pressure) 
and as a tocolytic to treat pre-term birth. The latter usage 
is prohibited in pregnant patients with pre-existing heart 
conditions. 
By applying discrete blocks to the L-Type calcium 
channels in each cell model we were able to simulate the 
presence of nifedipine at varying concentrations. Using 
the electrical and ionic responses to blocking these 
channels as indicators, we have been able to quantify and 
describe the effects of nifedipine in each cell type and 
compare them qualitatively. 
 Although any level of block will reduce the maximum 
level of intracellular calcium in the myometrial cell, a 
60% block or higher is required to produce a change in 
the morphology of the calcium transient. It remains to be 
shown if the dose required to achieve this could result in 
a patient with a pre-existing heart condition experiencing 
hypotension or other pathological cardiac conditions 
during labor, if nifedipine is used as a tocolytic. 
 
 
1. Introduction 
According to the World Health Organisation, pre-term 
birth and the subsequent complications are the leading 
cause of death amongst children under the age of 5 [1]. A 
contemporary approach to treating pre-term birth is the 
application of tocolytics; drugs that inhibit uterine 
contractions for 24-48 hours, in order to allow time for 
the mother to be relocated to a facility specialised in 
dealing with pre-term babies. Typically the baby must be 
treated with steroids to aid the maturation of its lungs. 
New tocolytics are being developed, as none of those 
currently available are ideal; for instance terbutaline is 
known to cause cardiac arrhythmias [2], and salbutamol 
cannot be used on diabetic patients [3]. 
Nifedipine is a common tocolytic used routinely by the 
National Health Service. It inhibits contraction of the 
uterus by blocking the calcium channels of myometrial 
cells. However, nifedipine also has other medical 
applications. It is used to manage angina pectoris, high 
EORRG SUHVVXUH DQG 5D\QDXG¶V SKHQRPHQRQ ± three 
cardiovascular conditions. It may even be used to treat 
severe high blood pressure in pregnant women. It should 
not be used on patients that suffer from low blood 
pressure, heart failure or disorders that affect muscle 
strength. 
Pre-term birth occurs in up to 10% of pregnancies. 
Using nifedipine as a tocolytic on the 0.5-1.0% of 
pregnant patients with pre-existing cardiac conditions 
poses a considerable risk. For instance, treatment may 
result in low blood pressure which can affect blood flow 
to the baby.  
Our investigation focuses on the behaviour exhibited 
by two types of cell that are affected by the application of 
nifedipine; ventricular myocytes and myometrial 
myocytes. Studying these cells simultaneously can 
provide insight into the effect of nifedipine on both the 
heart and uterus of a pregnant patient. Our objective was 
to investigate the characteristic behavioural changes 
experienced by these cells when they undergo calcium 
channel block.  
Computational models can offer a level of control 
when investigating changes to ion channel behaviour that 
is difficult to reproduce experimentally, due to the 
multitude of variables that must be managed. In this study 
we have used two computational models; one describing 
a rat ventricular cell and another describing a rat 
myometrial cell. 
 
2. Methods 
The ventricle cell is described by the Pandit et al 
model [4] and the myometrial cell by a modified Tong et 
al model [5]. Figure 1 shows the two cell models used, 
including each of the ion channels, pumps and 
exchangers. Detailed descriptions of these models can be 
found in the original publications. The modifications 
made to the Tong et al model will be published in future 
articles. 
The models use Hodgkin-Huxley type formulations to 
describe changes in the cell membrane potential (V) over 
time (t), known as the action potential (AP); the total 
membrane current (Itot) is divided by the membrane 
capacitance (Cm):  
 
 
 
Itot is calculated by summing up the individual ion 
currents shown in Figure 1. The L-Type calcium current 
(ICaL) plays an important role in the morphology of the 
action potential in both cell types.  
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Figure 1. Schematic cell diagrams of the Pandit et al 
model of the ventricular cell (top) and modified Tong et 
al model of the myometrial cell (bottom). All the 
channels, exchangers and pumps are included. Red 
arrows indicate a flow into the intracellular space, and 
blue a flow out. 
 
An AP leads to an influx of Ca2+ across the cell 
membrane, which in turn activates the process of 
calcium-induced calcium-release (CICR) from the 
sarcoplasmic reticulum (SR). As the concentration of 
calcium in the intracellular space ([Ca2+]i)  rises it binds 
to calmodulin, activating the myosin light-chain kinase 
(MLCK). Phosphorylated myosin can then form cross-
bridges with actin, causing the cell to contract. Myosin 
Light-Chain Phosphatase (MLCP) dephosphorylates the 
myosin leading to relaxation. 
In each cell the effects of nifedipine were simulated by 
reducing the conductance of the L-Type calcium channels 
at regular intervals of 20%. Each interval further reduces 
the availability of calcium in the cell, retarding the 
process of CICR and in turn, contraction. Observations 
were made of changes in the AP, [Ca2+]i and the L-Type 
calcium current. 
The ventricle cell was paced at 1 Hz, using a stimulus 
of -2 pApF-1 for 2 ȝs. The myometrial cell was stimulated 
at -0.33 pApF-1 for 1 s. This would be considered a very 
short contraction for a laboring uterine cell. Contractions 
in the human heart typically last for ~800 ms, whereas 
uterine contractions need to build up to about 1 minute 
before the cervix is able to dilate. Shorter uterine 
contractions have been selected for this paper purely on 
the basis that they are easier to visualize; the behavior 
demonstrated by the myometrial cell in this paper is 
replicated in the longer contractions (Figure 4). 
 
3. Results 
 
 
Figure 2. Changes in maximum levels of ICaL (top) and 
[Ca2+]i (bottom) under increasing levels of nifedipine. 0% 
block represents the WT condition. 
(1) 
  
Figure 3. A comparison of the influence of nifedipine on the AP, ICaL and [Ca2+]i of both the ventricle (left) and 
myometrial (right) myocytes. A and B: the APs. C and D: ICaL. E and F: [Ca2+]i A inset: the effect of each level of block 
on the APD90 of the ventricular cell. 
 
Applying nifedipine to each model caused significant 
changes in their electrical and ionic behavior. According 
to the findings shown in Figure 2, both models trivially 
experience a drop in ICaL with increasing block to the L-
Type calcium channels. However the uterine cell appears 
to be more resilient than the ventricular cell. This is 
further demonstrated by the much lower change in 
relative levels of [Ca2+]i. 
Figure 3 shows the influence of nifedipine on three 
important indicators of activity shared by both cell types:  
the AP, ICaL and [Ca2+]i.  
The AP of the ventricular cell is formed from a quick 
depolarizing upstroke followed by a slower drop back to 
the resting potential. The rate of this drop determines the 
action potential duration (APD). Calcium block causes a 
reduction in APD (Figure 3A), as the slope of the 
repolarization curve is largely determined by the 
opposing inward Ca2+ and outward K+ currents. The 
overall reduction in APD90 from 0% to 100% is from 94 
ms to 33 ms; a drop of 65%.  
[Ca2+]i in the ventricular cell (Figure 3E) undergoes a 
steady drop in amplitude as nifedipine block increases, 
echoing the effect on the AP and ICaL. The scale of the GURSJRLQJIURPWREORFNLVaȝ0DQGa
ȝ0JRLQJIURPWREORFN 
The myometrial AP is formed from an initial tall peak 
followed by a spike train with a frequency of 6 Hz 
(Figure 3B) when undergoing a constant stimulus. Up to a 
40% nifedipine block it undergoes only minor changes to 
its frequency, with a drop of ~15 mV in amplitude. 
However, from a 60% block the spike train is replaced 
with a plateau. The amplitude of the initial peak also 
drops as Ca2+ block increases, by ~15 mV between 0% 
and 100% block.  
 
 
 
Figure 4. Maximum [Ca2+]i values for myometrial cells 
under a 1 minute stimulus; a more realistic contraction 
duration. At these time scales the jump in maximum 
[Ca2+]i between 40% and 60% block becomes more 
pronounced. 
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The AP has a non-trivial correlation with the shape and 
amplitude of [Ca2+]i in the myometrial cell (Figure 3F). 
From 0% block to 40% block the amplitude of the AP and 
[Ca2+]i both fall by ~20%. And the abolition of the plateau 
in the AP is mirrored in the [Ca2+]i. However, after 60% 
block the AP undergoes very minor changes, whereas the 
[Ca2+]i continues to reduce. Once ICaL is blocked entirely 
[Ca2+]i remains constant. 
 
4. Discussion 
One possible explanation for the difference in relative 
change of [Ca2+]i in the ventricular and myometrial cells 
(Figure 2) is the influence of the T-Type calcium 
channels in the latter. The magnitude of the T-Type 
calcium current (ICaT) is approximately 10% of the value 
of ICaL. This means that although it has little effect under 
normal conditions, it becomes increasingly influential as 
the ICaL is gradually blocked. ICaT is not present in the 
Pandit et al model as this channel has little physiological 
significance in the ventricles. It should be noted that 
levels of [Ca2+]i do not increase beyond resting during the 
stimulated period when ICaL is blocked entirely, even with 
the presence of ICaT (Figure 3F). 
Applying nifedipine to the ventricular cell causes 
reductions in APD. A shortened APD can lead to a 
decrease in the effective refractory period (ERP). This 
can have a pro-arrhythmic effect, as it increases 
vulnerability to sustained re-entry. 
Nifedipine also causes a decrease in [Ca2+]i in the 
ventricular cell. This leads to a decrease in force and 
ventricular output, potentially resulting in hypotension. 
The initial peak of the myometrial AP is quite resilient 
to Ca2+ block; the subsequent spike train however is much 
more sensitive. It is useful to consider the morphology of 
the uterine AP in this study under two distinct domains: a 
spiked domain at blocks below 60% and a plateau domain 
above that threshold. Changes within these two domains 
are relatively minor. 
The rapid increases in [Ca2+]i caused by the spikes in 
the low-block domain are an important factor in the 
overall level of [Ca2+]i. Over long action potentials a 
significant difference in levels of [Ca2+]i will develop 
between the low and high-block domains (Figure 4). 
If we apply this same threshold of 60% block to the 
ventricular myocyte we note that the effect on heart 
function is potentially pathological. It would experience a 
reduction in APD90 of 48 ms (49%) DQGRIȝ0
in [Ca2+]i. From this we can infer a significant drop in 
ventricular output may occur. However, this conclusion 
assumes that ventricular cells and myometrial cells are 
equally sensitive to nifedipine, which is almost certainly 
not the case. Further studies must account for any 
differences in potency by applying experimental findings 
on the IC50 values for nifedipine in each cell type. 
 
Contemporary medical guidelines state that firstly, if 
nifedipine were to be used as a tocolytic on a patient with 
a pre-existing heart condition such as hypotension, then 
they are at risk of experiencing heart trouble before the 
dosage of nifedipine applied can reach sufficient levels to 
effectively halt uterine contraction.  
Secondly, if nifedipine were to be used as a means of 
managing high blood pressure in a pregnant patient then it 
could potentially have the additional effect of extending 
labor, if taken at sufficiently high doses, which may be 
undesirable. 
To summarize, in this study we have quantified some 
of the important changes that occur in both the heart and 
uterus of pregnant patients being treated with nifedipine. 
Both cell types experience reduced force output when 
nifedipine is applied due to the reduced intake of Ca2+ 
ions. There is potential for a patient to experience induced 
hypotension when nifedipine is used as a tocolytic to 
prolong labor. 
 
References 
[1] H. Blencowe, S. Cousens, M. Z. Oestergaard, D. Chou, A.-
B. Moller, R. Narwal, A. Adler, C. Vera Garcia, S. Rohde, 
L6D\DQG-(/DZQ³1DWLRQDOUHJLRQDODQGZRUOGZLGH
estimates of preterm birth rates in the year 2010 with time 
trends since 1990 for selected countries: a systematic 
DQDO\VLVDQGLPSOLFDWLRQV´The Lancet, vol. 379, no. 9832, 
pp. 2162±2172, Jun. 2012. 
[2] R. Michael Sly, J. A. Anderson, C. W. Bierman, P. 
Chervinsky, F. C. Cogen, J. G. Easton, I. Glazer, J. P. 
Kemp, A. Knight, R. A. Krumholz, R. A. Nicklas, B. M. 
Rudolph, D. E. Schuller, A. T. Segal, R. M. Sly, S. J. 
Szefler, M. J. Welch, N. J. Whitcomb, and M. Yamate, 
³$GYHUVHHIIHFWVDQGFRPSOLFDWLRQVRIWUHDWPHQWZLWKEHWD-
DGUHQHUJLFDJRQLVWGUXJV´J. Allergy Clin. Immunol., vol. 
75, no. 4, pp. 443±449, Apr. 1985. 
[3] J. L. Schlienger, M. J. Compagnie, P. Dellenbach, and F. 
6WHSKDQ ³>0HWDEROLF risks of salbutamol in diabetic 
SDWLHQWV $ VWXG\ XVLQJ VRPDWRVWDWLQ DXWKRU¶V WUDQVO@´
Nouv. Presse Médicale, vol. 9, no. 32, pp. 2247±2251, Sep. 
1980. 
[4] 693DQGLW5%&ODUN:5*LOHVDQG66'HPLU³$
mathematical model of action potential heterogeneity in 
DGXOW UDW OHIW YHQWULFXODU P\RF\WHV´ Biophys. J., vol. 81, 
no. 6, pp. 3029±3051, Dec. 2001. 
[5] W.-C. Tong, C. Y. Choi, S. Karche, A. V. Holden, H. 
=KDQJDQG0-7DJJDUW³$&RPSXWDWLRQDO0RGHORIWKH
Ionic Currents, Ca2+ Dynamics and Action Potentials 
Underlying Contraction of Isolated Uterine Smooth 
0XVFOH´PLoS ONE, vol. 6, no. 4, p. e18685, Apr. 2011. 
 
Address for correspondence. 
 
Craig P. Testrow, MPhys  
Room 3.21, Schuster Laboratory, School of Physics and 
Astronomy, The University of Manchester, Oxford Road, M13 
9PL 
craig.testrow@manchester.ac.uk  
